Tom Powles/X
Jan 26, 2025, 12:10
Tom Powles: Perioperative durvalumab + ctDNA are changing the muscle invasive bladder cancer
Tom Powles, Professor at the University of London, shared on X:
“The muscle invasive bladder cancer session AUC3 discussed perioperative durvalumab + ctDNA are changing the disease. Also, pCR of >50% is expected with EVP. Bladder sparing approaches after EVP is likely to be the standard of care if this is the case. ”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 06:51
Feb 24, 2025, 23:27
Feb 24, 2025, 15:25
Feb 24, 2025, 14:55
Feb 24, 2025, 14:51
Feb 24, 2025, 14:45
Feb 24, 2025, 14:22
Feb 24, 2025, 14:08
Feb 24, 2025, 14:00